Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Imunon, Inc. stock logo
CLSN
Imunon
$2.22
$1.80
$15.75
$13.91M2.27150,471 shs711 shs
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
$15.13
$14.82
$11.53
$15.89
$223.77M1.45396,929 shsN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$2.88
+0.2%
$2.55
$1.58
$5.02
$456.33M0.461.09 million shs799,203 shs
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
$0.65
-2.1%
$0.71
$2.08
$5.16
$5.58M-0.2639,197 shs48,968 shs
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$0.40
$0.10
$6.74
$423.91M0.772.19 million shs161,505 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Imunon, Inc. stock logo
CLSN
Imunon
0.00%0.00%0.00%0.00%0.00%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
0.00%+8.08%+12.75%+44.47%-19.92%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-2.10%-4.72%-3.56%-55.62%-85.51%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
1.9659 of 5 stars
3.63.00.00.00.61.70.0
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Imunon, Inc. stock logo
CLSN
Imunon
0.00
N/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
0.00
N/AN/AN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3.20
Buy$7.60164.35% Upside
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
0.00
N/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLSN, MREO, MACK, VBLT, and NRBO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/9/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Imunon, Inc. stock logo
CLSN
Imunon
$500K0.00N/AN/A$9.66 per share0.00
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$10M45.71N/AN/A$0.39 per share7.37
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/A$1.50 per shareN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$660K0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Imunon, Inc. stock logo
CLSN
Imunon
-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
-$1.18M$13.871.09N/AN/A-1.93%-1.78%N/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/A

Latest CLSN, MREO, MACK, VBLT, and NRBO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Imunon, Inc. stock logo
CLSN
Imunon
0.13
6.52
6.52
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A
10.78
10.78
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/A
8.92
8.92
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/A
2.41
2.41
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/A
4.63
4.63
CompanyEmployeesShares OutstandingFree FloatOptionable
Imunon, Inc. stock logo
CLSN
Imunon
277.10 million6.77 millionOptionable
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
42614.79 million10.27 millionOptionable
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
40159.00 million150.26 millionOptionable
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
108.62 million8.53 millionNot Optionable
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
777.64 million72.88 millionOptionable

Recent News About These Companies

AlboGraft Polyester Vascular Graft from LeMaitre
Tommy Garten elected to VBL Hall of Fame
Vascular News and Research
Notable Labs Closes Merger Transaction With VBL Therapeutics
Vascular Biogenics Rises on Presentation Hype

Media Sentiment Over Time

Imunon stock logo

Imunon NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Merrimack Pharmaceuticals stock logo

Merrimack Pharmaceuticals NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Mereo BioPharma Group stock logo

Mereo BioPharma Group NASDAQ:MREO

$2.88 +0.01 (+0.17%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$2.88 0.00 (0.00%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

NeuroBo Pharmaceuticals stock logo

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.65 -0.01 (-2.10%)
As of 07/3/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Vascular Biogenics stock logo

Vascular Biogenics NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.